Sumitomo Mitsui Trust Holdings Inc. Has $19.70 Million Position in Repligen Co. (NASDAQ:RGEN)

Sumitomo Mitsui Trust Holdings Inc. reduced its holdings in shares of Repligen Co. (NASDAQ:RGENFree Report) by 1.7% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 107,109 shares of the biotechnology company’s stock after selling 1,803 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned about 0.19% of Repligen worth $19,699,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Retirement Systems of Alabama boosted its position in shares of Repligen by 0.4% during the 4th quarter. Retirement Systems of Alabama now owns 65,032 shares of the biotechnology company’s stock valued at $11,693,000 after acquiring an additional 288 shares in the last quarter. Evoke Wealth LLC acquired a new position in Repligen in the fourth quarter valued at about $1,955,000. International Assets Investment Management LLC boosted its position in Repligen by 18,449.1% in the fourth quarter. International Assets Investment Management LLC now owns 58,615 shares of the biotechnology company’s stock valued at $10,539,000 after buying an additional 58,299 shares in the last quarter. Artemis Investment Management LLP boosted its position in Repligen by 33.8% in the first quarter. Artemis Investment Management LLP now owns 167,813 shares of the biotechnology company’s stock valued at $30,852,000 after buying an additional 42,380 shares in the last quarter. Finally, Congress Asset Management Co. MA boosted its position in Repligen by 14.6% in the first quarter. Congress Asset Management Co. MA now owns 88,013 shares of the biotechnology company’s stock valued at $16,187,000 after buying an additional 11,213 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Trading Up 0.9 %

RGEN opened at $120.82 on Wednesday. The firm’s fifty day moving average is $145.44 and its two-hundred day moving average is $170.98. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.24 and a current ratio of 6.35. The firm has a market cap of $6.75 billion, a PE ratio of 483.30, a price-to-earnings-growth ratio of 4.02 and a beta of 0.95. Repligen Co. has a twelve month low of $110.45 and a twelve month high of $211.13.

Repligen (NASDAQ:RGENGet Free Report) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.01). The firm had revenue of $151.31 million during the quarter, compared to analyst estimates of $150.06 million. Repligen had a return on equity of 3.95% and a net margin of 2.44%. The company’s revenue for the quarter was down 17.1% on a year-over-year basis. During the same quarter last year, the business posted $0.64 earnings per share. Equities research analysts anticipate that Repligen Co. will post 1.46 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Anthony Hunt bought 2,000 shares of the business’s stock in a transaction on Friday, June 14th. The shares were bought at an average cost of $124.08 per share, for a total transaction of $248,160.00. Following the completion of the acquisition, the chief executive officer now owns 165,177 shares in the company, valued at approximately $20,495,162.16. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CEO Anthony Hunt acquired 2,000 shares of the stock in a transaction dated Friday, June 14th. The stock was bought at an average price of $124.08 per share, with a total value of $248,160.00. Following the completion of the transaction, the chief executive officer now directly owns 165,177 shares of the company’s stock, valued at $20,495,162.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Martin D. Madaus acquired 1,615 shares of the stock in a transaction dated Friday, June 14th. The shares were bought at an average cost of $124.94 per share, with a total value of $201,778.10. Following the transaction, the director now directly owns 4,613 shares of the company’s stock, valued at $576,348.22. The disclosure for this purchase can be found here. Company insiders own 1.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on RGEN. Guggenheim began coverage on shares of Repligen in a research report on Tuesday, June 18th. They issued a “neutral” rating on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Repligen from a “hold” rating to a “buy” rating and reduced their price target for the company from $180.00 to $155.00 in a research report on Wednesday, June 26th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Thursday, May 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $193.00.

View Our Latest Stock Analysis on Repligen

Repligen Profile

(Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

See Also

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.